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Key Points
•DNA methylation sig-
natures can be used to
divide IGHV-mutated
CLL into clinically rele-
vant subgroups.
• The memory-like DNA
methylation subgroup is
an independent marker
of prolonged survival for
patients treated with
chemoimmunotherapy.
Chronic lymphocytic leukemia patients with mutated immunoglobulin heavy-chain genes
(IGHV-M), particularly those lacking poor-risk genomic lesions, often respond well to
chemoimmunotherapy (CIT). DNA methylation proﬁling can subdivide early-stage patients
into naive B-cell–like CLL (n-CLL), memory B-cell–like CLL (m-CLL), and intermediate CLL
(i-CLL), with differing times to ﬁrst treatment and overall survival. However, whether DNA
methylation can identify patients destined to respond favorably to CIT has not been
ascertained. We classiﬁed treatment-naive patients (n 5 605) from 3 UK chemo and CIT
clinical trials into the 3 epigenetic subgroups, using pyrosequencing and microarray
analysis, and performed expansive survival analysis. The n-CLL, i-CLL, andm-CLL signatures
were found in 80% (n 5 245/305), 17% (53/305), and 2% (7/305) of IGHV-unmutated (IGHV-U)
cases, respectively, and in 9%, (19/216), 50% (108/216), and 41% (89/216) of IGHV-M cases,
respectively. Multivariate Cox proportional analysis identiﬁed m-CLL as an independent
prognostic factor for overall survival (hazard ratio [HR], 0.46; 95% conﬁdence interval [CI], 0.24-
0.87; P5 .018) in CLL4, and for progression-free survival (HR, 0.25; 95% CI, 0.10-0.57; P5 .002) in
ARCTIC and ADMIRE patients. The analysis of epigenetic subgroups in patients entered into
3 ﬁrst-line UK CLL trials identiﬁes m-CLL as an independent marker of prolonged survival and
may aid in the identiﬁcation of patients destined to demonstrate prolonged survival after CIT.
Introduction
For many years, chemotherapy has been the mainstay of systemic therapy for patients with chronic
lymphocytic leukemia (CLL) who have progressive and/or symptomatic disease. The German CLL Study
Group CLL8 trial for previously untreated fit patients was the first to demonstrate that the addition of
rituximab to fludarabine and cyclophosphamide (FCR) prolonged both progression-free survival (PFS)
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and overall survival (OS) compared with FC.1 Longer follow-up of
patients receiving first line chemoimmunotherapy (CIT) with FCR
both in CLL8 and in large observational studies shows a major sur-
vival benefit in the subgroup of patients with mutated immunoglob-
ulin heavy chain variable genes (IGHV-M) lacking a TP53 deletion,
who may achieve prolonged disease-free survival and OS.2-5
Targeted therapeutic agents have further improved patient out-
comes, and recent reports suggest superiority of first-line ibrutinib
with or without rituximab compared with CIT.6-8 However, long-term
outcome data from studies comparing standard CIT with novel
agents will be unavailable for many years, and in the interim, there
remains clinical value in identifying novel biomarkers to refine the
subgroup of patients who are most likely to achieve long-term
survival with minimal toxicity after treatment with CIT.9
New insights have emerged from global DNA methylation profiling
of normal B-cell subsets and large CLL cohorts, using both
microarrays and whole-genome bisulphite sequencing.10,11 Using
genome-wide analysis, patients with CLL can be grouped into
3 distinct epigenetic subclasses, namely, naive B-cell–like CLL
(n-CLL), memory B-cell–like CLL (m-CLL), and intermediate CLL
(i-CLL), that partially reflect the stage of B-cell maturation from
which their tumors are derived. Queiro´s et al identified 5 epigenetic
DNAmethylation markers that are able to classify patients into these
epigenetic subgroups with high accuracy.12 The authors demon-
strated that the methylation of these markers is stable over time, and
they and others have validated the utility of this classification system
for predicting time to first treatment and OS in retrospective studies
of predominantly early-stage patients.12
Although these data suggest that epigenetic classification repre-
sents a novel independent prognostic factor with potential clinical
utility, its importance has not been validated in the context of clinical
trials. To address this, we have studied 605 patients entered into
UK chemotherapy and CIT trials. With this approach, we identify
m-CLL as an independent marker of prolonged survival that may aid
in the identification of patients destined to demonstrate protracted
survival after CIT.
Methods
Patients, samples, and biomarker data
We studied treatment-naive patients entered into 3 randomized
clinical trials, aiming to assess chemo and CIT; the UK Leukaemia
Research Fund Chronic Lymphocytic Leukaemia 4 trial (UK LRF
CLL4 [ClinicalTrials.gov identifier: NCT00004218]; n 5 777),
which compared chlorambucil and fludarabine with or without
cyclophosphamide,13 and the UK National Cancer Research
Network phase IIB trials, ADMIRE (ADM, UKCRN ID6897; n 5
216),14 a randomized trial that compared the efficacy of FCR
against FCR and mitoxantrone, and ARCTIC (ARC, UKCRN
ID7136; n 5 196),15 which compared FCR with FC, mitoxantrone,
and low-dose rituximab (Table 1). All patients were diagnosed using
standard morphologic and immunophenotypic criteria. Informed
consent was obtained from all patients in accordance with the
Declaration of Helsinki, and the Somerset Regional Ethics
Committee approved the study.
Material was available from 605 cases, with 124, 122, and 359
cases from ARC, ADM, and CLL4, respectively (supplemental
Figure 1). No selection bias, except for age at randomization for
ARC cases, was observed for samples selected to this current
study compared with those of the entire trials (supplemental
Table 1). All samples were taken at trial entry before initiation of
treatment. The assessment of established biomarkers including
FISH, CD38, ZAP70, and IGHVmutational status was performed as
previously described.13 For CLL4, data on VH usage and IGHV
stereotype were available. TP53, NOTCH1, and SF3B1 mutations
were identified using a TruSeq Custom Amplicon panel (Illumina
Inc., San Diego, CA) for ARC and ADM, and using a combination of
molecular approaches for CLL4 (eg, high-resolution melt analyses
combined with Sanger sequencing), as previously reported.16-19
Methylation analyses
Before DNA extraction (DNeasy Blood & Tissue Kit, Qiagen),
CD51/CD191 B cells from ARC/ADM patients were purified using
the EasySep Human B Cell enrichment kit (StemCell Technolo-
gies). Tumor purity of greater than 80% was confirmed with
fluorescence-activated cell sorter analysis. For CLL4, historical
DNA samples were used, extracted from samples with more than
80% tumor cells. For each case, 500 ng DNA underwent bisulfite
modification, using the EZ-96 DNA Methylation-Gold Kit (ZymoR-
esearch) before pyrosequencing (n 5 605), or 450K methylation
array analysis (n5 60). Pyrosequencing assays for 5 CpGs located
in the promoter region of SCARF1 (cg00869668); in the gene
body of B3GNTL1 (cg11472422), CTBP2 (cg17014214), and
TNF (cg09637172); and in chromosome 14 intergenic region
(cg03462096) were quantified (PyroMark Q24) in all available
samples in triplicate (for primer sequences and additional method-
ological details, see supplemental Methods; supplemental Table 2).
Table 1. Basic clinicobiological features of the ARC, ADM, and CLL4
trials
Variable ADM ARC CLL4
Patients, n 122 124 359
Age at randomization, median (range), y 62 (39-77) 61 (36-80) 64 (41-86)
Sex, n (%)
Male 97 (80) 90 (73) 270 (75)
Female 25 (20) 34 (27) 89 (25)
Binet stage, n (%)
A 15 (12) 23 (18.5) 93 (26)
B 61 (50) 62 (50.5) 155 (43)
C 46 (38) 39 (31) 111 (31)
IGHV mutational status, n (%)
IGHV-U 60 (52) 65 (60) 180 (61)
IGHV-M 56 (48) 43 (40) 117 (39)
del(11q), n (%)
Absent 98 (81) 98 (82) 256 (78)
Present 23 (19) 22 (18) 72 (22)
del(17p), n (%)
Absent 111 (92) 111 (95) 300 (93)
Present 10 (8) 6 (5) 23 (7)
Epigenetic subgroup, n (%)
n-CLL 52 (43) 60 (49) 186 (52)
i-CLL 36 (29) 34 (27) 125 (35)
m-CLL 34 (29) 30 (24) 48 (13)
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To confirm our pyrosequencing-based classification, 60 DNA
samples were also processed with the 450k Human Methylation
Array (Illumina), and data were normalized by the bMixture Quantile
method, using RnBeads.20 Epigenetic classification was performed
using both pyrosequencing and 450k data with the support vector
machine-learning (SVM) tool described by Queiros et al.12
Statistical analysis
As a result of similarities in inclusion criteria and outcome data,
ARC and ADM patients were examined together. Furthermore, the
2 cohorts were not statistically significantly different for a panel
of clinicobiological parameters14,15 (supplemental Table 3). As
a consequence, for clinical associations and survival analysis, 2
cohorts were examined: 356 patients from CLL4, and 228 ARC/
ADM cases. The effect of epigenetic subgroups on OS and PFS
was assessed using Kaplan-Meier survival plots (log-rank test) and
Cox proportional hazards analyses. Multivariable Cox regression
models were used to evaluate the independent prognostic
significance of the epigenetic classification. A step-wise backward
elimination procedure was applied to an initial multivariable model
that included all potential predictors with available data. The least
significant variable was excluded from the initial model, one at
a time, each time generating a new model. These steps were
repeated until a final model was arrived at with only the significant
predictors.
Overall response status in CLL4 was defined as complete or
nodular partial response, partial response or nonresponse, or
progressive disease. In ARC and ADM, minimal residual disease
and treatment response were assessed at 3 months posttreatment,
with the latter defined as complete remission and partial remission.
In all trials, PFS was defined as the time from randomization to
progression (ie, relapse needing further treatment) or death, or to
the last clinical follow-up date for those who were alive with no
progression. OS was defined as the time from randomization to
death or to the last follow-up date for survivors, and was only
assessed in the CLL4 study because of the limited follow-up in ARC
and ADM. The clinicobiological associations were evaluated using
the Pearson x2 and Mann-Whitney U tests. All reported P values
were 2-sided and were considered significant at the 5% level.
Outcome data for PFS from CLL4 and ARC/ADM (January 2017
for ARC/ADM, October 2010 in CLL4), and OS from CLL4
(September 2016), were analyzed with STATA (v12.1) and SPSS
(v23). Power calculations are shown in supplemental Methods.
Results
Microarray validation of pyrosequencing data
We employed pyrosequencing with subsequent SVM to classify
605 patients with CLL from the CLL4 and ARC/ADM cohorts into
3 epigenetic subgroups, as previously described. In doing so,
we identified n-CLL, i-CLL, and m-CLL in 49.3% (n 5 298), 32.2%
(n 5 195), and 18.5% (n 5 112) of our patients, respectively
(supplemental Table 4; supplemental Figure 2A). The accuracy of
our pyrosequencing-based classification was validated in 60 cases,
using the same SVM-based classification and b-values from the
Infinium HumanMethylation450 BeadChip array. This comparison
demonstrated a 95% concordance between techniques (57/60
cases; supplemental Figure 2B).
Epigenetic signature subgroups associate with key
clinicobiological features
Immunoglobulin gene locus. Initially, we looked for any
associations between the epigenetic subgroups and key structural
features of the IGHV locus (supplemental Table 4). In our pooled
cohort, we observed a significant association between epigenetic
subgroup and IGHV status (P , .001; supplemental Table 4). The
n-CLL, i-CLL, and m-CLL signatures were found in 80% (n 5 245/
305), 17% (53/305), and 2% (7/305), respectively, of IGHV-
unmutated (IGHV-U) CLL cases and in 9%, (19/216), 50% (108/
216), and 41%, (89/216), respectively, of IGHV mutated (IGHV-M)
cases (supplemental Table 4; supplemental Figure 3A). In CLL4,
analysis of IGHV sequences available from 288 cases showed
a significant association between epigenetic subgroup and
mutational load (supplemental Figure 3B) and IGHV family usage
(supplemental Table 4 and Figure 3C). The median IGHVmutational
load differed between epigenetic subgroups (P , .001), with
n-CLL, i-CLL, and m-CLL cases exhibiting 100%, 96.65% (95%
confidence interval [CI], 96.27%-97.5%), and 92.90% (95% CI,
91.61%-94.37%) median homology to germline, respectively
(supplemental Figure 3B). We then focused our analysis on IGHV
mutational load in IGHV-M and IGHV-U cases exhibiting a n-CLL or
m-CLL epigenetic subgroup, respectively, and showed in both
situations that these cases exhibited IGHVmutational loads close to
the 98% cutoff, with IGHV-M/n-CLL and IGHV-U/m-CLL cases
showing a mean IGHV germline homology of 96.35% and 98.6%,
respectively. Seventy-four percent (14/19) of stereotyped subset
#2 cases were i-CLL (P, .001), with remaining cases classified as
n-CLL (supplemental Table 4). n-CLL accounted for 94% (47/50)
of IGHV1-69 cases (P , .001), and i-CLL accounted for 60% (12/
20, P 5 .016), 74% (17/23, P , .001), and 42% (8/19, P 5 .011)
of IGHV3-21, IGHV3-23, and IGHV4-34 cases, respectively
(supplemental Table 4; supplemental Figure 3C). In ARC/ADM,
analysis of IGLV sequences from 192 patients21 showed a signif-
icant association between epigenetic subgroup and expression of
the IGLV3-21 gene (P , .001), with expression in 16% (14/87),
58% (29/50), and 17% (8/47) of n-CLL, i-CLL, and m-CLL cases,
respectively (supplemental Figure 3D). Elevated ZAP70 expression
in patients with CLL4 was significantly associated with epigenetic
subgroup (P , .001), with the majority of ZAP70-positive cases
displaying n-CLL epigenetic signature (supplemental Table 4;
supplemental Figure 4A), which was an expected observation,
given its strong association with IGHV status.22
Genomic abnormalities. Next, we assessed the relation-
ship between epigenetic classification and the presence and
absence of CLL-specific genomic lesions (supplemental Table 4;
supplemental Figure 4A). Sixty-eight percent (80/117; P, .001) of
cases with deletion of 11q, 77% (41/53, P, .001) with trisomy 12,
and 72% (33/46; P 5 .015) with mutations in the TP53 gene were
n-CLL (supplemental Table 4). Deletion of 17p was not associ-
ated with the epigenetic classification. Cases with mutations in
NOTCH1 (including the 39 UTR; P5 .011) and SF3B1 (P5 .024)
were also associated with epigenetic classification and enriched in
the n-CLL and i-CLL subgroups, respectively.
Telomere length. In 245 CLL4 cases with data available,23
the median telomere length (TL) differed between epigenetic
subgroups (P , .001), with n-CLL, i-CLL, and m-CLL cases
exhibiting 2.83 kb (95% CI, 2.55-3.11 kb), 3.07 kb (95% CI,
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2.66-3.98 kb), and 5.04 kb (95% CI, 3.72-6.74 kb) median TL,
respectively (supplemental Figure 4B). Categorizing TL using our
published cutoffs, the n-CLL epigenetic subgroup displayed 6%
(8/135), 35% (47/135), and 59% (80/135) cases with long,
intermediate, and short telomeres, respectively (P , .001). In the
m-CLL group, long, intermediate, and short TL was present in
85% (23/27), 0% (0/27), and 15% (4/27), respectively (P ,
.001; supplemental Figure 4C).
i-CLL. Given the significant associations observed between
i-CLL and a number of genomic and immunogenetic features, we
studied 139 CLL4 cases with complete data available for IGHV
mutational load, TL, IGHV3-21, subset #2, and SF3B1 mutations
(supplemental Figure 4D). This analysis demonstrated that i-CLL
shows evidence of further subdivision into cases with and without
intermediate IGHV mutational load and a high prevalence of the
concomitant immunogenomic features, IGHV3-21, subset #2, and
SF3B1 mutations; the latter 3 have been previously shown to
coexist .24
Prognostic effect of epigenetic signatures in patients
treated with chemotherapy
Univariate Cox regression analysis. Because of the
cohort size and the availability of long-term follow-up data, we
initially investigated the clinical importance of epigenetic subgroup
in the CLL4 cohort (n 5 359). We did not find any statistically
significant association between epigenetic subgroups and overall
response status in CLL4, neither overall (supplemental Table 5) nor
in individual trial treatment arms (supplemental Table 6). Of the 183
cases with data available on the cause of death, only 4 were a result
of Richter transformation, and all 4 cases were in the n-CLL
subgroup.
Clinicobiological features significantly associated with PFS and OS
in univariate Cox proportional hazards analyses are shown in
supplemental Tables 7 and 8. Patients with n-CLL, i-CLL, and
m-CLL exhibited median PFS times of 23 (95% CI, 17.9-26.2), 35
(95% CI, 23.3-40.4), and 33.3 (95% CI, 23.8-48.1) months,
respectively. Univariate Cox regression modeling showed that when
compared with the n-CLL subgroup, the risk for progression for the
patients in the m-CLL and i-CLL subgroups was reduced by 46%
(hazard ratio [HR], 0.54; 95% CI, 0.38-0.78; P 5 .001) and 34%
(HR, 0.66; 95% CI, 0.52-0.84; P 5 .001), respectively (supple-
mental Table 7; Figure 1A). For OS, the n-CLL, i-CLL, and m-CLL
patients exhibited median survival times of 62.8 (95% CI, 52.2-
71.8), 66.5 (95% CI, 54.4-90.7), and 105.9 (95% CI, 100.9-111.8)
months, respectively (supplemental Table 8; Figure 1B). Both
patients with m-CLL and patients with i-CLL experienced a re-
duction in the risk for death by 67% (HR, 0.33; 95% CI, 0.21-0.52;
P , .001) and 27% (HR, 0.73; 95% CI, 0.56-0.94; P 5 .017),
respectively, compared with patients in the n-CLL subgroup. We
also observed a statistically significant difference in risk for death
between i-CLL and m-CLL (HR for m-CLL, 0.46; 95% CI, 0.28-
0.73; P 5 .001; supplemental Table 8). In further support of the
significant association between the m-CLL subgroup and pro-
longed OS, 46% (22/48) of patients with m-CLL survived for more
than 10 years compared with 27% (34/124) and 14% (26/185) of
i-CLL and n-CLL cases, respectively (P 5 .001; supplemental
Table 9). In a limited cohort of IGHV-M cases, significantly more
patients with m-CLL survived more than 10 years (50%, 18/36)
than those defined as i-CLL or n-CLL (31%, [25/81]; P 5 .039;
supplemental Table 9).
Next, we evaluated survival in the IGHV-U or IGHV-M subgroups of
CLL4. We did not observe a significant association between
epigenetic subgroup and PFS in either of the IGHV subgroups
(supplemental Figure 5A; supplemental Table 10). However, among
IGHV-M patients, the m-CLL subgroup remained significantly
associated with favorable OS when compared with both patients
with i-CLL (HR, 0.52; 95% CI, 0.29-0.92; P 5 .017) and patients
with n-CLL (HR, 0.35; 95% CI, 0.16-0.78; P 5 .01; supplemental
Figure 5B; supplemental Table 10). The IGHV-U subgroup lacked
sufficient cases in the m-CLL subgroup, thus precluding a meaning-
ful analysis in these patients (supplemental Table 10).
Multivariate Cox regression analysis. We then estimated
the adjusted prognostic effect of epigenetic classification on OS
and PFS after controlling for potential confounders employing
multivariate Cox proportional hazards analysis with stepwise back-
ward selection. Our initial analysis (Analysis I) focused on
biomarkers that were available for the majority of patients across
CLL4 and ARC/ADM cohorts. The final model for PFS (with
only significant variables) Analysis I in the CLL4 cohort did not
identify epigenetic subgroup as an independent prognostic marker
(supplemental Table 11). When the same clinicobiological variables
were entered into a model for OS, the m-CLL epigenetic signature
(HR, 0.46; 95% CI, 0.24-0.83; P 5 .021) was identified as
a favorable prognostic biomarker. Age (HR, 1.06; 95% CI, 1.04-
1.08; P, .001) and stage of the disease (A versus B1C; HR, 1.44;
95% CI, 1.04-2.00; P 5 .026) were unfavorable prognostic factors
(Table 2). Next, we developed a model that included additional
molecular biomarkers (Analysis II); specifically, the presence of key
gene mutations (Table 2). This model was based on a smaller
sample size (PFS: 191 patients/177 events; OS: 278 patients/
217 events) because of data availability. Inclusion of additional
biomarkers did not diminish the prognostic significance of the
m-CLL epigenetic subgroup in OS for patients in CLL4 (HR, 0.46;
95% CI, 0.24-0.87; P 5 .018; Table 2).
Prognostic effect of epigenetic signature in CIT trials
Univariate Cox regression analysis. Next, we evaluated
the clinical significance of epigenetic subgroups in patients treated
with CIT in the ARC/ADM cohort. Although treatment response
was not associated with epigenetic classification (supplemental
Table 12), we demonstrated a significant association between
epigenetic subgroup and minimal residual disease status (P5 .033;
supplemental Table 13), where 61% (38/62) of patients with
m-CLL achieved a minimal residual disease-negative response.
Patients with n-CLL and i-CLL epitypes exhibited median PFS times
of 47.3 (95% CI, 42.0-52.6) and 72.5 (95% CI, 56.7-88.3) months,
respectively, and 71% of patients with an m-CLL epitype had not
progressed at their last follow-up (therefore, median PFS was not
reached; Figure 1C). We demonstrated that the i-CLL subgroup
exhibited a 51% reduction in the risk for progression (HR, 0.49;
95% CI, 0.33-0.73; P, .001) compared with n-CLL (supplemental
Table 14). Patients in the m-CLL subgroup exhibited a 75% (HR,
0.25; 95% CI, 0.15-0.42; P , .001) and 49% (HR, 0.51; 95% CI,
0.29-0.91; P5 .02) reduction in their risk for progression compared
with the n-CLL and i-CLL groups, respectively (supplemental
Table 14; Figure 1C). For the IGHV-M patients alone, we observed
27 AUGUST 2019 x VOLUME 3, NUMBER 16 DNA METHYLATION IN CLINICAL TRIALS OF CLL 2477
.For personal use only on August 30, 2019. at INSTITUTE OF CANCER RESEARCH www.bloodadvances.orgFrom 
a trend toward longer PFS for patients with m-CLL (HR, 0.32; 95%
CI, 0.1-1.10; P 5 .07) when compared with patients with n-CLL
(supplemental Figure 6; supplemental Table 15). In a further refined
analysis, focusing on 87 IGHV-M patients with wild-type TP53,
n-CLL and i-CLL epitypes exhibited median PFS times of 30.4
(95% CI, 12.1-48.7) and 85.4 (95% CI, 48.0-122.75) months,
respectively. Median PFS was not reached for patients with the
m-CLL epitype because of insufficient progressions in this group.
Importantly, the n-CLL patients exhibited a significant increased risk
for PFS (HR, 4.09; 95% CI, 1.14-14.66; P 5 .031) compared with
m-CLL (supplemental Figure S7).
Multivariate Cox regression analysis. Next, we analyzed
2 multivariate models for our ARC/ADM patients, in line with our
previous analysis of CLL4 cases. In Analysis I (236 patients with
132 progressions; Table 3), we demonstrated that the i-CLL (HR,
0.59; 95% CI, 0.39-0.90; P 5 .014) and m-CLL epigenetic
subgroup (HR, 0.23; 95% CI, 0.14-0.40; P , .001), del(11q) (HR,
1.70; 95% CI, 1.15-2.52; P 5 .008) and del(17p) (HR, 6.03; 95%
CI, 3.31-10.97; P , .001), retained independent prognostic
significance. In Analysis II (Table 3), accounting for additional gene
mutations (TP53, SF3B1, and NOTCH1) in a cohort of 125
patients (80 progressions), we demonstrated that the m-CLL
epigenetic subgroup (HR, 0.25; 95% CI, 0.10-0.57; P 5 .002),
del(11q) (HR, 2.36; 95% CI, 1.36-4.11; P 5 .002) and del(17p)
(HR, 3.87; 95% CI, 1.66-9.01; P 5 .002) and TP53 mutation (HR,
3.28; 95% CI, 1.54-7.00; P 5 .002), retained independent
prognostic significance.
Discussion
Patients with CLL can be classified into 3 epigenetic subgroups
(naive, intermediate, and memory) according to global DNA
methylation patterns that partially reflect the changes in methylation
that occur during the maturation of normal naive to memory B cells;
namely, prominent hypomethylation, especially of enhancer and
promotor regions, and gene bodies, together with hypermethylation
in regions of transcriptional elongation.10,11 Using a pyrosequenc-
ing assay targeting 5 CpGs, which accurately identifies these
subgroups, Queiro´s and coworkers12 and a subsequent Swedish
analysis of predominantly Binet stage A patients25 confirmed the
previous epigenomic analysis showing a strong correlation between
n-CLL and m-CLL with IGHV-U and IGHV-M, respectively.
Combining data from both studies, the intermediate subgroup
(i-CLL) comprised 15% of cases, of which approximately 80% were
IGHV-M CLL with a median identity to germline of 96%. Importantly,
both studies established the clinical significance of this assay,
showing that epigenetic subgroups were an independent marker of
time to first treatment and OS in retrospective, early-stage
cohorts.12,25
Novel targeted therapies are revolutionizing the management of
CLL. However, long-term follow-up of patients treated with first-line
FCR show that the subset of cases with IGHV-M CLL lacking TP53
abnormalities may achieve long-term disease-free survival.2-5
However, these studies also suggest that 20% to 30% of IGHV-
M cases have a suboptimal outcome after FCR that is not obviously
attributable to poor-risk genomic abnormalities. The ability of an
epigenetic assay to subdivide cases of IGHV-M CLL with differing
clinical outcomes therefore has potential relevance for the selection
of previously untreated patients who might achieve long-term
survival after CIT. To address this, we undertook an epigenetic
analysis of 3 UK-based clinical trials, assessing the utility of DNA
methylation in therapy-naive patients with CLL at first-line treatment
with chemotherapy or CIT.
We assessed the methylation status of the 5 CpGs in 605 patients
enrolled onto the CLL4, ARC, and ADM trials, and found n-CLL,
i-CLL, and m-CLL in 49.5%, 32.0%, and 18.5% of patients,
respectively. As in previous studies,12,25 the i-CLL signature was
more prevalent in IGHV-M than in IGHV-U CLL, comprising 50% of
the former and only 17% of the latter. The higher incidence of i-CLL
in the current study likely reflects the more advanced clinical stage
of the trial cohorts; for example, in our study, Binet stage A patients
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Figure 1. The prognostic importance of epigenetic subgroups in patients from the UK CLL4, ARC, and ADM clinical trials. n-CLL, i-CLL, and m-CLL, classified by
pyrosequencing, are depicted in green, orange, and blue, respectively. Kaplan-Meier survival curves for the 3 epigenetic subgroups for PFS (A) and OS (B) in CLL4 and for
PFS in ARC/ADM cases (C). (A) The median PFS was 23, 35, and 33 months for the n-CLL (n 5 186), i-CLL (n 5 125), and m-CLL (n 5 48) subtypes, respectively. (B)
Median OS was 62.8, 66.5, and 105.9 months for n-CLL (n 5 186), i-CLL (n 5 125), and m-CLL (n 5 48), respectively. (C) Median PFS for n-CLL (n 5 112), i-CLL (n 5 70),
and m-CLL (n 5 64) was 30.4 months, 85.4 months, and not reached, respectively. The P values are derived from Kaplan-Meier analysis with log-rank test.
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comprised 22% of cases compared with 83% in published studies,
many of whom had long-term stable disease.
In multivariate analyses that included a comprehensive panel of
clinical features and biomarkers, m-CLL was an independent marker
of prolonged PFS in the ARC/ADM cohort, and of OS in CLL4.
Furthermore, in IGHV-M patients of CLL4, the m-CLL subgroup
remained significantly associated with favorable OS when com-
pared with both i-CLL and n-CLL. Much larger studies would be
required to ascertain the prognostic significance of the small subset
of cases with m-CLL and unmutated IGHV genes and to confirm
that cases of IGHV-M CLL with n-CLL respond poorly to CIT.
However, these cases whose epigenetic subtype and IGHV
mutational status appears discordant have IGHV homology close
to the arbitrary 98% cutoff, and may not represent biologically
distinct subsets.
The explanation for the prognostic significance of the i-CLL
subgroup, especially those cases within the IGHV-M subgroup,
with which they share a comparable chromatin landscape, remains
unclear.26 We confirm the association of i-CLL with subset #2
(24% of i-CLL) and SF3B1 mutations (26%), and also show
enrichment of cases expressing the IGLV3-21 gene (62%), with
64% (32/50) of i-CLL cases with data available, harboring 1 of
these features. The associations among i-CLL, low IGHV mutational
load, and intermediate TL are also likely to be clinically relevant,
although the later requires further validation in additional cohorts.
IGHV mutational load, assessed as a continuous variable, was
recently shown to associate with outcome in patients treated with
FCR,27 and we previously noted TL to have clinical utility in the
CLL4 trial.23
The strengths of our study are the large prospective nature of the
cohorts, the uniformity of treatment, the assessment of multiple
clinical endpoints (PFS and OS), the long follow-up in the CLL4
cases, and the expansive clinicobiological information available
for comparison, including the presence of key recurrent gene
mutations. The main limitations are the restricted OS data available
for the ARC/ADM cohorts and the dated treatment modality
employed in the 359 CLL4 patients. However, the observation that
TP53, SF3B1, and RPS15mutations remain poor-risk factors in the
German CLL8 trial comparing FCR vs FC,28 and the likelihood of
a global need for chemotherapy in CLL for the foreseeable future,
indicate that genomic data from the UK CLL4 trial will continue to
have clinical relevance. The pyrosequencing assay employed here
is simple to implement and interpret, and readily classified
patients into the 3 epigenetic subgroups. However, genome-wide
approaches have shown that the degree of B-cell maturity-based
DNA methylation changes within each epigenetic subtype is
associated with clinical outcome,10 variation that cannot be
detected by this current pyrosequencing assay. It is therefore
possible that more expansive methylation analysis may provide
additional prognostic information.
Table 2. Multivariate Cox proportional hazard analyses of OS in the
CLL4 trial
Significant variables HR (95% CI) P
Analysis I
Epigenetic subgroup
n-CLL — —
i-CLL 0.77 (0.52-1.13) ns
m-CLL 0.46 (0.24-0.83) .021
IGHV status (IGHV-M vs -U) 0.62 (0.40-0.90) .014
del(17p) (present vs absent) 5.19 (3.19-8.45) ,.001
Age 1.06 (1.04-1.08) ,.001
Stage (A vs B1C) 1.44 (1.04-2.00) .026
Analysis II
Epigenetic subgroup
n-CLL —
i-CLL 0.82 (0.56-1.20) ns
m-CLL 0.46 (0.24-0.87) .018
IGHV status (IGHV-M vs -U) 0.60 (0.40-0.90) .014
del(17p) (present vs absent) 5.01 (3.08-8.14) ,.001
Age 1.06 (1.04-1.07) ,.001
Two multivariable models were built (Analysis I and II) for the OS of UK CLL4 patients
using a step-wise backward elimination process. The 2 models shown here include all
significant predictors remaining at the end of the backward elimination analyses. Analysis I:
Variables included at the start of the backward elimination process were epigenetic
subgroups, age at randomization, sex, treatment, stage, IGHV mutational status, del(11q),
and del(17p). The final model was based on 278 patients and 217 deaths. Analysis II: The
variables included in the model initially were epigenetic subgroups, age at randomization,
sex, treatment, stage, IGHV mutational status, del(11q), del(17p), TP53 mutation, combined
NOTCH1 coding, and 39UTR mutations and SF3B1 mutations. The final model was based
on 278 patients and 217 events.
ns, nonsignificant.
Table 3. Multivariate Cox proportional hazard analysis of PFS in the
ARCTIC-ADMIRE trials
Significant variables HR (95%CI) P
Analysis I
Epigenetic subgroups
n-CLL — —
i-CLL 0.59 (0.39-0.90) .014
m-CLL 0.23 (0.14-0.40) ,.001
del(11q) (present vs absent) 1.70 (1.15-2.52) .008
del(17p) (present vs absent) 6.03 (3.31-10.97) ,.001
Analysis II
Epigenetic subgroups
n-CLL — —
i-CLL 0.89 (0.50-1.59) ns
m-CLL 0.25 (0.10-0.57) .002
del(11q) (present vs absent) 2.36 (1.36-4.11) .002
del(17p) (present vs absent) 3.87 (1.66, 9.01) .002
TP53 mutation (present vs absent) 3.28 (1.54-7.00) .002
Two multivariable models were built (Analysis I and II) for the progression-free survival
(PFS) of patients from ARCTIC/ADMIRE, using a step-wise backward elimination process.
The 2 models shown here include all significant predictors remaining at the end of the
backward elimination analyses. Analysis I: Variables included at the start of the
backward elimination process were epigenetic subgroups, age, sex, treatment, stage,
IGHV mutational status, del(11q), and del(17p). The final model was based on 236
patients and 132 progressions. Analysis II: The variables included in the model initially
were epigenetic subgroups, age, sex, treatment, stage, IGHV mutational status,
del(11q), del(17p), TP53 mutation, combined NOTCH1 coding and 39UTR mutations
and SF3B1 mutations. The final model was based on 125 patients and 80 events.
Estimates (95% CI) and P values for IGHV-mutation status (IGHV-M v -U) were HR,
0.58 (95% CI, 0.31-1.07; P 5 .082; Analysis I) and HR, 0.56 (95% CI, 0.23-1.34;
P 5 .195; Analysis II).
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In conclusion, we present the first study to validate the clinical
importance of the cell-of-origin, epigenetic subtype signature in the
context of multiple randomized, prospective clinical trials. In doing
so, we validate and extend key associations between epigenetics
and clinicobiological disease features. Importantly, we identify
m-CLL as an independent marker of survival in both our LRF
CLL4 and ARC/ADM cohorts. Future studies should focus on the
further validation of this methodology in the context of other large
FCR cohorts, such as the CLL8 study and the ongoing UK MRC
FLAIR trial, and in trials of anti-CD20 antibodies in combination
with less intensive chemotherapy regimens. Furthermore, test-
ing clinical utility of these epigenetic subgroups in the context
of targeted agents is critical, particularly for ibrutinib, in which
evidence suggests limited prognostic significance of IGHV
status 29. Finally, standardization and harmonization of the
approach will be paramount for the implementation of this
approach into routine clinical use. Taken together, our data
provide evidence that DNA methylation analysis may aid in the
identification of patients destined to achieve prolonged survival
when treated with FCR-based CIT.
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